"We closed another quarter of solid execution and superior growth, all while enhancing our capability to reach more customers and the capacity to manage increasing case volumes," said Sam Riccitelli, Genoptix EVP and COO. "Our staff has expanded to include 44 sales representatives and 19 Cartesian hematopathologists on-site to service our more than 850 ordering physicians nationwide, as we continue to effectively pace our expansion relative to our growing customer base."
Based on second quarter results and the recent confirmation of Medicare reimbursement rates, Genoptix is adjusting its performance outlook upward for the full-year 2008, and now expects revenues of between $105 and $108 million, up from the most recent guidance of between $90 and $95 million, which was provided following the first quarter of 2008.
Net income expectations for the year are moving up from the previously provided range of between $15 and $17 million to approximately $20 million for the year, assuming an average annual tax rate of 5%. This includes the impact of an estimated $7 million in non-cash stock-based compensation for 2008, an increase resulting primarily from expenses associated with the initiation of the Company's equity incentive programs. Diluted GAAP EPS, which includes non-cash stock-based compensation of approximately $0.40 per share, is now expected to be between $1.11 and $1.16 on an estimated 17.6 million shares for the full year 2008.
Based on continued infrastructure expansion and implementation of its
strategic plan, the Company is now projecting capital expenditures of
approximately $11.0 million for the full-year 2008, up from prior estimates
of approximately $6.0 millio
|SOURCE Genoptix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved